Correction to: The Pharmacogenomics Journal (2016) 16: 530-535; doi:10.1038/tpj.2015.63
In the published version of this article, some funding sources were omitted in the Acknowledgments section. The correct Acknowledgments appears below. The authors regret the error.
Acknowledgements
We thank all patients and their parents who consented to participate in genetics studies related to leukemia. The Canadian Institutes of Health Research, Canadian Cancer Society, Canadian Cancer Research Society, C17 Council, Pediatric Oncology Group of Ontario and the Hospital for Sick Children's Garron Family Center supported this study. We thank Kristen Stevenson for retrieving the DFCI data. Dana-Farber Cancer Institute ALL treatment protocols are supported by the National Cancer Institute/NIH grant 5 P01CA068484.
Additional information
The online version of the original article can be found at 10.1038/tpj.2015.63
Rights and permissions
About this article
Cite this article
Krajinovic, M., Elbared, J., Drouin, S. et al. Erratum: Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J 17, 107 (2017). https://doi.org/10.1038/tpj.2016.86
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2016.86
This article is cited by
-
Genetics of Anthracycline-Mediated Cardiotoxicity: Current Status and Challenges
Current Cardiovascular Risk Reports (2020)
-
Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity
Current Oncology Reports (2018)
